Latigo Biotherapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Latigo Biotherapeutics, Inc. (LTGO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.14 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-03.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-09-03
- Latigo Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.14M, a 27.79% increase year-over-year.
- Latigo Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.98M, a 34.10% increase year-over-year.
- Latigo Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.68M.
- Latigo Biotherapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $1.48M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month |
|---|---|---|
| 2026-06-30 | $2.14M 10-Q · filed 2026-09-03 | $4.12M derived: sum of 2 quarters · filed 2026-09-03 |
| 2026-03-31 | $1.98M 10-Q · filed 2026-09-03 | |
| 2025-06-30 | $1.68M 10-Q · filed 2026-09-03 | $3.15M derived: sum of 2 quarters · filed 2026-09-03 |
| 2025-03-31 | $1.48M 10-Q · filed 2026-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |